Analyst firms · Barclays · LGND
Barclays LGND price target and rating history
Ligand Pharmaceuticals Incorporated (LGND) · Health Care
Barclays rates Ligand Pharmaceuticals Incorporated (LGND) Overweight with a $345 price target, as of its latest action on Sep 25, 2026. It has published 3 rating actions on LGND since September 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a LGND price target in the last 12 months, the median target is $345. Barclays's target matches it.
- Current rating
- Overweight
- Price target
- $345
- Median target, all firms
- $345
- Actions on LGND
- 3
Barclays price target on LGND
Every Barclays rating on LGND
- Sep 25, 2026
- Feb 18, 2022
- Sep 22, 2021
How other firms rate LGND
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $345 | Sep 25, 2026 |
| Leerink Partners | Outperform | Aug 14, 2026 | |
| Citigroup | Buy | $387 | Jul 21, 2026 |
| BofA Securities | Buy | $244 | Mar 11, 2026 |
Questions about Barclays and LGND
- What is Barclays's price target for LGND?
- Barclays's latest stated price target for Ligand Pharmaceuticals Incorporated (LGND) is $345, from its action on Sep 25, 2026.
- What is Barclays's rating on LGND?
- Barclays rates LGND Overweight, a bullish rating, as of Sep 25, 2026.
- When did Barclays last change its view on LGND?
- On Sep 25, 2026, Barclays starts coverage at Overweight, price target $345.
- How does Barclays's LGND target compare with other analysts?
- Across 3 firms with a LGND price target in the last 12 months, the median target is $345. Barclays's target matches it.
All Barclays ratingsLGND news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.